But that move is probably not enough, because the publisher Hindawi uncovered this past spring. Although Hindawi doesn’t let authors suggest reviewers because of their manuscripts, it made a decision to examine the peer-review information for manuscripts submitted in 2013 and 2014 for possible fraud. The peer-review procedure used in Hindawi’s journals depends primarily on the expertise of its editorial board members and the guest editors of special issues, who are in charge of supervising the review of submitted manuscripts.5 Because the peer reviewers chosen by the guest editors were not subject to any sort of independent verification, editors themselves could undermine the process in quite similar way that authors or third-party agencies did elsewhere: by creating fake reviewer identities and addresses that they submitted positive reviews endorsing publication.Abbvie presents venetoclax Phase 1 results in sufferers with multiple myeloma in ASCO 2015 AbbVie , a global biopharmaceutical company, today announced that outcomes from a Phase 1b trial of investigational venetoclax, a novel inhibitor of the B-cell lymphoma-2 protein that’s being developed in partnership with Genentech and Roche, in combination with dexamethasone and bortezomib, showed an 83 % overall response price in bortezomib-naive individuals with relapsed/refractory multiple myeloma, including two individuals who achieved complete responses.1 These data will be presented at the American Society of Clinical Oncology Annual Conference on Sunday, May 31, in Chicago.